EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Evaluation of Rabeprazole for Gastrointestinal Protection in Acute Coronary Syndrome Patients Treated with Aspirin and Ticagrelor: A Pilot Study

Hye Kyung Hyun iD, Oh-Hyun Lee iD, Ji Woong Roh iD, Seok-Jae Heo iD, Cheal Wung Huh iD, Yongcheol Kim iD

Yonsei Medical Journal · 2025

DOI: 10.3349/ymj.2025.0232 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Yonsei Medical Journal, 2025. Verfasst von Hye Kyung Hyun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea. Hauptthemen laut MEDLINE: Rabeprazole, Acute Coronary Syndrome, Ticagrelor, Aspirin. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Patients with acute coronary syndrome (ACS) on ticagrelor-based dual antiplatelet therapy (DAPT) have an increased risk of gastrointestinal (GI) bleeding. However, evidence supporting the protective role of proton pump inhibitors against DAPT-induced gastric mucosal injury remains limited. MATERIALS AND METHODS: This was a single-center, prospective, open-label, observational trial enrolling patients with ACS who were treated with DAPT, specifically aspirin and ticagrelor, following percutaneous coronary intervention in South Korea. Participants received 20 mg rabeprazole once daily for 8 weeks. The primary outcome was the proportion of patients exhibiting a modified Lanza score (MLS) of 0-5 on upper endoscopy at 8 weeks compared to baseline endoscopy results. The secondary outcomes included GI symptom scores and safety assessments. RESULTS: Among the 50 patients included in the per-protocol analysis, the median MLS at baseline and 8 weeks was 2.0 (1.0-2.0) and 2.0 (1.0-2.0), respectively, with no significant change (p=0.69). Similarly, in patients at high-risk for GI bleeding (76.0%, 38/50), there was no significant difference in MLS after 8 weeks of treatment with rabeprazole compared to the baseline MLS, consistent with the results of the overall study population. GI symptom scores, including the Nepean Dyspepsia Index-Korean, Gastroesophageal Reflux Disease (GERD) Questionnaire, and GERD Health-Related Quality of Life Questionnaires, showed no significant changes from baseline in the overall cohort and high-risk groups. No major bleeding or adverse cardiac events were observed. CONCLUSION: In this pilot study, rabeprazole was associated with maintained gastric mucosal integrity in patients with ACS receiving ticagrelor-based DAPT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RabeprazoleAcute Coronary SyndromeTicagrelorAspirinPlatelet Aggregation InhibitorsProton Pump InhibitorsHumansFemaleMalePilot ProjectsMiddle AgedAgedProspective StudiesGastrointestinal Hemorrhage

Stichwörter der Autor:innen

Rabeprazoleacute coronary syndromegastric mucosagastrointestinal hemorrhageticagrelor

Substanzen

RabeprazoleTicagrelorAspirinPlatelet Aggregation InhibitorsProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea.
  • Division of Cardiology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine and Cardiovascular Center, Yongin, Korea.
  • Division of Biostatistics, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea. huhcw@yuhs.ac.
  • Division of Cardiology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine and Cardiovascular Center, Yongin, Korea. yongcheol@yuhs.ac.

ORCID-Profile: Hye Kyung Hyun, Oh-Hyun Lee, Ji Woong Roh, Seok-Jae Heo, Cheal Wung Huh, Yongcheol Kim

Zitieren

APA

Hyun, H. K., Lee, O. H., Roh, J. W., Heo, S. J., Huh, C. W., & Kim, Y. (2025). Evaluation of Rabeprazole for Gastrointestinal Protection in Acute Coronary Syndrome Patients Treated with Aspirin and Ticagrelor: A Pilot Study. Yonsei Medical Journal. https://doi.org/10.3349/ymj.2025.0232

Vancouver

Hyun HK, Lee OH, Roh JW, Heo SJ, Huh CW, Kim Y. Evaluation of Rabeprazole for Gastrointestinal Protection in Acute Coronary Syndrome Patients Treated with Aspirin and Ticagrelor: A Pilot Study. Yonsei Medical Journal. 2025. doi:10.3349/ymj.2025.0232

BibTeX
@article{Hyun2025,
  author = {Hyun, Hye Kyung and Lee, Oh-Hyun and Roh, Ji Woong and Heo, Seok-Jae and Huh, Cheal Wung and Kim, Yongcheol},
  title = {Evaluation of Rabeprazole for Gastrointestinal Protection in Acute Coronary Syndrome Patients Treated with Aspirin and Ticagrelor: A Pilot Study},
  journal = {Yonsei Medical Journal},
  year = {2025},
  doi = {10.3349/ymj.2025.0232}
}
Kostenlos starten →